Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Bicycle Therapeutics plc (NASDAQ:BCYC) will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The company's management will discuss its proprietary bicyclic peptide technology. A live webcast and replay of the event will be available on the company's website.
02/07/2024 - 07:00 AM
CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle® ) technology, today announced that management will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024, at 10 a.m. ET.
A live webcast of the fireside chat will be accessible from the Investor section of the company’s website, www.bicycletherapeutics.com . A replay of the webcast will be archived and available following the event.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC® ) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2; and BT7480, a Bicycle TICA® targeting Nectin-4 and agonizing CD137, in company-sponsored Phase 1/2 trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in a Phase 1/2a clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle Therapeutics is headquartered in Cambridge, UK , with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207654804/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544
Media:
Argot Partners
Deborah Elson
media@bicycletx.com
212-600-1902
Source: Bicycle Therapeutics plc
When will Bicycle Therapeutics plc participate in the fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference?
Bicycle Therapeutics plc will participate in the fireside chat on February 14, 2024.
What is the ticker symbol for Bicycle Therapeutics plc?
The ticker symbol for Bicycle Therapeutics plc is BCYC.
What will the management discuss at the fireside chat?
The management will discuss its proprietary bicyclic peptide technology.
Where can the live webcast of the fireside chat be accessed?
The live webcast can be accessed from the Investor section of the company’s website, www.bicycletherapeutics.com.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be archived and available following the event.
BCYC Rankings
#4392 Ranked by Stock Gains
BCYC Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Biotechnology, Pharmaceuticals: Major, Health Technology
Country
United Kingdom
City
Cambridge
About BCYC
bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun